This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Neurology				
Neuropathy	Histone deacetylase 6 (HDAC6); heat shock 27 kDa protein 1 (HSPB1; HSP27); tubulin	<p>Mouse studies suggest HDAC6 inhibitors could help treat Charcot-Marie-Tooth (CMT) disease caused by <i>HSP27</i> mutations. Transgenic mice expressing mutant <i>Hsp27</i> in neurons had CMT disease-like sensorimotor defects compared with controls expressing wild-type <i>Hsp27</i>. In the mutant mice, HDAC6 inhibitors increased motor performance compared with vehicle. Future studies could include testing HDAC6 inhibition in animal models of CMT disease caused by other gene mutations.</p> <p>ACY-1215, an oral selective HDAC6 inhibitor from Acetylon Pharmaceuticals Inc., is in preclinical testing to treat multiple myeloma (MM) and other cancers.</p> <p>KAR3166, an HDAC6 inhibitor from Karus Therapeutics Ltd., is in preclinical testing to treat inflammation. The company's KAR3000 HDAC6 inhibitor is in lead optimization to treat cancer.</p> <p>SciBX 4(30); doi:10.1038/scibx.2011.860 Published online Aug. 4, 2011</p>	Patent and licensing status unavailable	<p>D'Ydewalle, C. <i>et al. Nat. Med.</i>; published online July 24, 2011; doi:10.1038/nm.2396</p> <p>Contact: Ludo Van Den Bosch, Catholic University Leuven, Leuven, Belgium e-mail: ludo.vandenbosch@vib-kuleuven.be</p>